The Maharashtra Food and Drug Administration (FDA) has officially issued showcause notices to Bollywood icons Shah Rukh Khan, Ajay Devgn, and Tiger Shroff regarding their involvement in advertisements for Vimal Elaichi. This regulatory action, spearheaded by FDA official Tukaram Mundhe, demands that the three actors provide a formal explanation within a 15-day window. The move targets the promotion of products that critics argue are surrogate advertisements for pan masala, a segment that has faced significant scrutiny from health authorities over the past few years.
Shah Rukh faces regulatory inquiry
The core of the legal contention rests on the nature of the branding used in these high-profile campaigns. While the product is marketed as cardamom-based mouth freshener, regulators contend that it functions as a surrogate for tobacco-related pan masala brands. Under current Maharashtra state regulations, authorities have intensified their efforts to curb the visibility of products associated with health risks. The agency is now requiring these celebrities to clarify their role in these commercial endorsements as part of a broader crackdown on deceptive advertising practices within the tobacco and stimulant industry.
This administrative push has ignited a wider debate regarding the ethical responsibility of A-list stars when choosing brand partnerships. As the scrutiny intensifies, other industry figures have weighed in on the issue. Notably, actor Sunny Deol has publicly distanced himself from such promotional work, explicitly stating that his personal conscience prevents him from endorsing products linked to health hazards. His stance has gained traction in public discourse, highlighting a growing tension between lucrative commercial contracts and the social influence wielded by top-tier film personalities.
With the 15-day deadline set by the Maharashtra FDA, all eyes are on how the actors and their legal teams will respond to the state’s directive. Failure to provide a satisfactory explanation could potentially lead to further regulatory steps. For now, the move represents a significant escalation in the government’s attempts to hold celebrities accountable for their influence on consumer health, signaling a potential shift in how surrogate advertising will be policed across the Indian entertainment landscape moving forward.